Senior Director, Marketing - Germline Portfolio
Tempus AI
Summary
The Senior Director, Marketing - Germline Portfolio, is a visionary leader responsible for the strategic direction, brand development, and commercial success of the company's hereditary cancer testing (HCT) and germline portfolio. This role oversees the commercial lifecycle of hereditary screening tools, ensuring they deliver medically actionable insights that empower patients and clinicians to manage cancer risk proactively. You will bridge the gap between technical NGS development and high-impact commercial execution, leading the innovation of market-facing narratives for high-penetrance genes and expanded panels.
Job description
Responsibilities
- Differentiated Positioning & Narrative Execution: Develop and execute a comprehensive commercial roadmap for the germline portfolio, with a particular emphasis on hereditary cancer and rare disease testing at the point-of-care (in-clinic use cases). Own the overarching narrative to ensure the market understands our unique value proposition in VUS resolution and family-member testing programs.
- Downstream Commercial Strategy: Drive product positioning, messaging, and go-to-market (GTM) strategies. Lead the development of physician marketing, patient-advocacy engagement, and digital clinician portals to streamline genetic counseling workflows.
- Sales Enablement & Training: Partner deeply with Sales and Learning & Development (L&D) to equip the field organization with high-impact materials and aligned messaging to maximize clinical adoption.
- Cross-Functional Synergy: Act as a bridge between R&D, Medical Affairs, and Laboratory Operations to ensure marketing strategies remain scientifically accurate and comply with regulatory requirements (FDA, CLIA, CAP).
- Followership Over Mandate: You possess the organic authority and humility to listen deeply, collaborate cross-functionally, and rally multiple departments behind a unified marketing vision.
- Low Ego, High Impact: You view marketing as a team sport, working seamlessly with technical, medical, and sales peers to turn growth strategy into commercial success without needing to own the entire upstream architecture.
Required Education & Experience
- Education: Bachelor's degree in Life Sciences required; MBA, MS in Genetic Counseling, or PhD preferred to bridge the gap between complex science and business strategy.
- Experience: 10+ years of direct marketing experience in healthcare or life sciences, with at least 5 years in a senior leadership role focused on oncology, advanced diagnostics, or germline genetics.
- Domain Expertise: Deep understanding of Next-Generation Sequencing (NGS) workflows, cancer genomics, and the evolving landscape of hereditary cancer testing.
- AI-First Mindset: Practical familiarity with utilizing or operationalizing digital tools and modern AI-driven workflows to enhance the customer experience and marketing efficiency.
Requirements
- Bachelor's degree in Life Sciences required
- MBA, MS in Genetic Counseling, or PhD preferred
- 10+ years of direct marketing experience in healthcare or life sciences
- At least 5 years in a senior leadership role focused on oncology, advanced diagnostics, or germline genetics
- Deep understanding of Next-Generation Sequencing (NGS) workflows, cancer genomics, and the evolving landscape of hereditary cancer testing
- Practical familiarity with utilizing or operationalizing digital tools and modern AI-driven workflows
Benefits
- Incentive Compensation
- Restricted Stock Units
- Medical Benefits
Company overview
Tempus AI, Inc. (NASDAQ: TEM) is a pioneering healthcare technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. The company was established after Lefkofsky's wife was diagnosed with breast cancer, driving his mission to revolutionize cancer care through technology and artificial intelligence. Tempus specializes in applying AI to advance precision medicine by collecting and analyzing vast amounts of molecular, clinical, and genomic data. The company operates across multiple therapeutic areas including oncology, cardiology, radiology, neurology, psychiatry, and dermatology. Tempus provides comprehensive diagnostic services including next-generation sequencing (NGS), PCR profiling, and molecular pathology testing. Its AI-powered platform enables physicians to make real-time, data-driven decisions for personalized patient care and targeted therapies. The company went public in June 2024 and has expanded globally with operations in multiple countries. Tempus continues to innovate at the intersection of healthcare and artificial intelligence, aiming to ensure patients receive the right treatments at the right time for improved health outcomes.